​
​

Esperion Therapeutics Ownership | Who Owns Esperion Therapeutics?

OverviewForecastRevenueFinancialsChartTranscripts

Esperion Therapeutics Ownership Summary

Esperion Therapeutics is owned by 80.80% institutional investors, 0.50% insiders, and 18.70% retail investors. Wasatch advisors lp is the largest institutional shareholder, holding 9.96% of ESPR shares. BB Biotech AG Ord is the top mutual fund, with 5.07% of its assets in Esperion Therapeutics shares.

ESPR Ownership Benchmark

TypeName% Inst% Insiders% Retail
StockEsperion Therapeutics80.80%0.50%18.70%
SectorHealthcare Stocks 47.06%8.01%44.93%
IndustrySpecialty & Generic Drug Manufacturers Stocks33.68%9.20%57.12%

Institutional Shareholders

Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Wasatch advisors lp16.86M9.96%$37.44M
Blackrock13.98M8.26%$31.04M
Vanguard group10.82M6.39%$24.01M
Bellevue group9.94M5.88%$22.08M
Two seas capital lp5.74M3.39%$12.73M
Woodline partners lp5.05M2.98%$11.21M
Marshall wace, llp4.30M2.54%$9.55M
Geode capital management4.16M2.46%$9.24M
Two sigma investments, lp4.07M2.41%$9.05M
Two sigma advisers, lp3.87M2.29%$8.60M

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Meditor group3.79M15.57%$8.42M
Two seas capital lp5.74M2.07%$12.73M
Diametric capital, lp743.84K0.90%$1.65M
Rhenman & partners asset management ab1.98M0.42%$4.38M
Bellevue group9.94M0.36%$22.08M
Parkman healthcare partners1.14M0.34%$2.54M
Centerbook partners lp1.57M0.22%$3.48M
Wasatch advisors lp16.86M0.20%$37.44M
Virtus etf advisers113.18K0.12%$251.25K
Platinum investment management1.20M0.11%$2.66M

Top Buyers

HolderShares% AssetsChange
Blackrock13.98M0.00%11.14M
Wasatch advisors lp16.86M0.20%7.73M
State street3.75M0.00%3.20M
Geode capital management4.16M0.00%2.41M
Nuveen asset management2.27M0.00%2.27M

Top Sellers

HolderShares% AssetsChange
Orbimed advisors---13.71M
Great point partners---5.79M
D. e. shaw382.49K0.00%-4.76M
Bank of america corp /de/1.16M0.00%-3.38M
Woodline partners lp5.05M0.11%-2.87M

New Positions

HolderShares% AssetsChangeValue
Nuveen asset management2.27M0.00%2.27M$5.05M
Rhenman & partners asset management ab1.98M0.42%1.98M$4.38M
Centerbook partners lp1.57M0.22%1.57M$3.48M
Deutsche bank ag\1.53M0.00%1.53M$3.40M
Ci private wealth182.50K0.00%182.50K$405.15K

Sold Out

HolderChange
Assetmark-8.00
Signaturefd-342.00
Deepcurrents investment group-890.00
First manhattan co. llc.-1.00K
Wetzel investment advisors-5.00K

Institutional Ownership Trends

DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Jun 30, 202419314.20%136,759,0259.15%800.65%10912.37%287.69%
Mar 31, 202416916.55%125,298,78674.83%1112.72%9751.56%26-35.00%
Dec 31, 20231458.21%71,670,941-7.32%641.28%6410.34%4025.00%
Sep 30, 2023134-2.19%77,332,8893.99%700.79%587.41%32-17.95%
Jun 30, 2023137-25.14%74,368,075-8.15%940.89%54-44.33%39-18.75%

Top Mutual Funds Shareholders

HolderShares% HoldingChange
BB Biotech AG Ord9.94M5.07%-
Wasatch Ultra Growth6.68M3.40%-
Vanguard Total Stock Mkt Idx Inv6.18M3.16%-
iShares Russell 2000 ETF4.87M2.48%-10.95K
Wasatch Small Cap Growth Investor4.40M2.24%1.49M
Wasatch Micro Cap4.21M2.15%903.59K
Vanguard Institutional Extnd Mkt Idx Tr2.58M1.31%42.42K
Vanguard Explorer Inv2.32M1.18%1.33M
Rhenman Healthcare Equity L/S RC2 SEK1.98M1.01%-
Fidelity Small Cap Index1.94M0.99%-47.73K

Recent Insider Transactions

DateNameRoleActivityValue
Oct 17, 2024Warren Eric Chief Commercial OfficerSell$226.73
Sep 17, 2024Koenig Sheldon L. President and CEOSell$26.13K
Sep 17, 2024Warren Eric Chief Commercial OfficerSell$4.65K
Aug 19, 2024Warren Eric Chief Commercial OfficerSell$410.61
Jul 17, 2024Warren Eric Chief Commercial OfficerSell$279.40

Insider Transactions Trends

DateBuySell
2024 Q4-1
2024 Q3-5
2024 Q2-3
2024 Q1--
2023 Q3-3

ESPR Ownership FAQ

Who Owns Esperion Therapeutics?

Esperion Therapeutics shareholders are primarily institutional investors at 80.80%, followed by 0.50% insiders and 18.70% retail investors. The average institutional ownership in Esperion Therapeutics's industry, Specialty & Generic Drug Manufacturers Stocks, is 33.68%, which Esperion Therapeutics exceeds.

Who owns the most shares of Esperion Therapeutics?

Esperion Therapeutics’s largest shareholders are Wasatch advisors lp (16.86M shares, 9.96%), Blackrock (13.98M shares, 8.26%), and Vanguard group (10.82M shares, 6.39%). Together, they hold 24.62% of Esperion Therapeutics’s total shares outstanding.

Does Blackrock own Esperion Therapeutics?

Yes, BlackRock owns 8.26% of Esperion Therapeutics, totaling 13.98M shares as of Jun 2024. This represents 0.00% of BlackRock's total assets, with a market value of 31.04M$. In the last quarter, BlackRock increased its holdings by 11.14M shares, a 392.59% change.

Who is Esperion Therapeutics’s biggest shareholder by percentage of total assets invested?

Meditor group is Esperion Therapeutics’s biggest shareholder by percentage of total assets invested, with 15.57% of its assets in 3.79M Esperion Therapeutics shares, valued at 8.42M$.

Who is the top mutual fund holder of Esperion Therapeutics shares?

BB Biotech AG Ord is the top mutual fund holder of Esperion Therapeutics shares, with 5.07% of its total shares outstanding invested in 9.94M Esperion Therapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools